The ultimate goal of muscular dystrophy gene therapy is to treat all muscles in the body. Global gene delivery was demonstrated in dystrophic mice more than a decade ago using adeno-associated virus (AAV). However, translation to affected large mammals has been challenging. The only reported attempt was performed in newborn Duchenne muscular dystrophy (DMD) dogs. Unfortunately, AAV injection resulted in growth delay, muscle atrophy and contracture. Here we report safe and bodywide AAV delivery in juvenile DMD dogs. Three ∼2-m-old affected dogs received intravenous injection of a tyrosine-engineered AAV-9 reporter or micro-dystrophin (μDys) vector at the doses of 1.92-6.24 × 10 14 viral genome particles/kg under transient or sustained immune suppression. DMD dogs tolerated injection well and their growth was not altered. Hematology and blood biochemistry were unremarkable. No adverse reactions were observed. Widespread muscle transduction was seen in skeletal muscle, the diaphragm and heart for at least 4 months (the end of the study). Nominal expression was detected in internal organs. Improvement in muscle histology was observed in μDys-treated dogs. In summary, systemic AAV gene transfer is safe and efficient in young adult dystrophic large mammals. This may translate to bodywide gene therapy in pediatric patients in the future.
Introduction
Localized gene transfer has resulted in miraculous improvements for diseases that affect a single organ (1, 2) . However, such therapies will unlikely change the disease course when afflicted tissues are distributed throughout the body as in the case of Duchenne muscular dystrophy (DMD), a lethal X-linked muscle disease caused by dystrophin deficiency (3) . The ultimate cure for DMD requires bodywide gene therapy. Vascular delivery has the potential of global muscle transduction. However, infusion of trillions of viral particles may lead to unexpected responses and even fatal complications (4, 5) .
The first successful whole body gene transfer was conducted in rodent models of muscular dystrophy more than a decade ago using adeno-associated virus (AAV). Investigators from several laboratories demonstrated that a single intravascular injection of AAV-6, 8 or 9 reached every muscle in the body (6) (7) (8) . More recently, systemic AAV delivery was achieved in skeletal and cardiac muscle of aged dystrophic mice (9) (10) (11) . Despite marvelous results in rodents, bodywide gene transfer has been problematic in diseased large mammals (12) .
Systemic gene transfer in a large mammal was initially tested in normal neonatal dogs (13, 14) . Intravenous injection of 2 × 10 14 viral genome (vg) particles/kg of AAV-9 resulted in broad skeletal muscle transduction in puppies (13) . The same technique was subsequently found to be effective for other AAV serotypes (15) (16) (17) . In these studies, persistent expression was achieved for up to 1 year (the end of the study) at a dose as high as 9.7 × 10 14 vg particles/kg without any toxicity. Unfortunately, translation to the canine DMD model has met with great difficulties (18) . Kornegay et al. delivered 1.5 × 10 14 vg particles/kg of AAV-9 to two 4-day-old affected puppies through the jugular vein. Surprisingly, treated dogs developed massive inflammatory myopathy, contracture and growth retardation (5) . The results of Kornegay et al. question the feasibility of systemic AAV gene therapy in dystrophic large mammals. Recent studies suggest that replacing surface exposed tyrosine residue on AAV capsid may reduce immunogenicity and enhance transduction (19, 20) . We tested Y731F AAV-9, a surface tyrosine mutated AAV-9 variant in adult DMD dogs and observed robust expression following direct muscle injection (21) . Here we tested the hypothesis that Y731F AAV-9 can result in whole body muscle transduction in juvenile DMD dogs. A human placental alkaline phosphatase (AP) reporter vector or a potentially therapeutic μDys vector were injected intravenously at a dose up to 6.24 × 10 14 vg particles/kg under transient or sustained immune suppression. All three dogs tolerated injection and immune suppression well. No adverse reactions were observed. Necropsy at the age of 5.5-6 months revealed robust skeletal muscles transduction throughout the body and widespread gene transfer in the heart. Our results demonstrated for the first time that systemic AAV delivery in a diseased large mammal is safe and effective. Similar approaches may be used to treat pediatric muscular dystrophy patients in the future.
Results
A single intravenous injection of Y731F AAV-9 resulted in efficient skeletal muscle transduction throughout the body and widespread gene transfer in the heart Dog Bouchelle was injected with 1.92 × 10 14 vg particles/kg (7.09 × 10 14 vg particles total) of a Rous sarcoma virus (RSV)
promoter-driving AP reporter AAV vector (Table 1 ). This dog also received 5-week transient immune suppression (Fig. 1A) (21, 22) . The injection procedure went smoothly. The dog tolerated immune suppression and large-dose AAV well. No change was noted in the activity, behavior, food/water consumption and vital signs of the dog throughout the entire experiment. The body weight also showed stable growth (Table 1 and Fig. 1B) . Compared with that of the baseline (before the start of immune suppression), post-injection blood chemistry was in general unremarkable (Fig. 1C , and Supplementary Material, Table S1 ). There was a slight increase in blood urine nitrogen (but still within the normal range), a trend of higher creatine (but still within the normal range), and transient elevation of blood AP (Fig. 1C) . However, we did not detect any clinically meaningful events. One-month muscle biopsy showed strong AP expression and abundant vector genomes ( Fig. 1D and E) . Bouchelle was euthanized at 3.5 months after gene transfer. AAV transduction was evaluated by histochemical staining, enzymatic activity assay and vector genome quantification (Figs 2 and 3) . We observed widespread AP expression and vector genome in every muscle (Fig. 2) . On average, ∼25% (range, 5-80%) myofibers were transduced. The extensor carpi ulnaris (ECU) muscle had the lowest expression (AP positive myofiber, 5%; AP activity, 0.84 μM/μg). The highest transduction was seen in the extraocular muscle (EOM) (AP positive myofiber, 80%; AP activity, 215 μM/μg; AAV genome copy number, 26.2 copies/diploid genome). Respiratory failure and heart failure are the leading causes of death in DMD. Encouragingly, high-level AP expression was detected in the diaphragm, intercostal muscle and heart (Fig. 2) .
Systemic Y731F AAV-9 injection resulted in minimal expression in internal organs
On histochemical staining, we did not detect AP expression in the liver and testis (Fig. 3A) . In the kidney, we found very few AP positive cells in the glomerulus (Fig. 3A) . In the lung, AP positive cells were seen in alveolar cells. In the pancreas, we noticed strong AP expression in smooth muscle and some expression in acini (Fig. 3B) . However, minimal expression was observed in islets of Langerhans (Supplementary Material, Fig. S1 ). Robust transduction was observed in the microvasculature in muscles (Fig. 3C) . The peripheral nerves (including large nerves such as sciatic nerve and small nerve branches inside muscle) showed very high AP expression ( Fig. 3D and E) . The spinal cord was also transduced at high efficiency (Fig. 3E ). Some AP expression was seen in the hippocampus, but minimal AP expression was detected in the cerebrum and cerebellum (Fig. 3E) . Consistent with AP staining results, the AP activity assay in tissue lysate revealed minimal expression in internal organs except for the sciatic never and spinal cord (Fig. 3F) . Despite the dramatic difference in AP expression, surprisingly, similar amount of the AAV genome was detected in internal organs (Fig. 3F) . In fact, the AAV genome copy number in internal organs was quite comparable to that in muscles ( Figs 2D and 3F) . Table S1 ). Essentially, all laboratory parameters were within the range of other affected dogs in our colony. One-month biopsy revealed robust μDys expression (Fig. 1D) . Necropsy was performed at 3.5 (Stephan) and 4 (Brooke) months after injection. Consistent with the findings of Bouchelle, we observed efficient gene transfer in (Fig. 4E ). Similar to Bouchelle (Fig. 2) , the EOM showed the highest transduction (50-60%) while the ECU muscle had the least μDys expression (5%) (Fig. 4A, B and E). Respiratory muscles (diaphragm, intercostal muscle and abdominal muscle) were also highly transduced with 23-48% myofibers showed μDys expression. Western blot with a dystrophin antibody confirmed μDys expression at the expected size in striated muscles ( Fig. 4F and G). The AAV vector genome was detected in every muscle ( Fig. 3G and H) . No μDys was detected in internal organs (Supplementary Material, Fig. S2 ).
μDys expression reduced histopathology
In Bouchelle, the dog that received the AP reporter vector, all muscles showed classic dystrophic pathology such as abundant inflammatory cell infiltration, dark-stained hyalinized/hypercontracted myofibers, necrotic myofibers, angulated myofibers, large hypertrophic myofibers, excessively small myofibers and increased endomysial and perimysial connective tissue deposition (Fig. 5A , and Supplementary Material, Fig. S3 ). For dogs that received the μDys vector (Stephan and Brooke), two different profiles were observed. The majority of muscles had ≥25% μDys-positive cells (such as the abdominal muscle, biceps femoris (BF), cranial tibialis (CT) and triceps brachii (TB)). These muscles appeared to have relatively uniformed myofiber size and much less inflammation (Fig. 5) . Hyalinized/hypercontracted myofibers were rarely detected in these muscles. On detailed immunohistochemical characterization, we observed very few macrophages, neutrophils, CD4+ T cells and CD8+ T cells ( Fig. 5B and C) . Further, these inflammatory cells were restricted to small loci ( Fig. 5B and  C) . A different profile was seen in the ECU muscle. This muscle had the lowest expression (5%) (Fig. 4E) . Its histology was identical to that of untreated or AAV.AP injected DMD dogs (data not shown). On in situ force measurement, we did not see any improvement (data not shown).
To study overall improvement in μDys-treated dogs, we examined the serum CK level but did not see a consistent trend (Supplementary Material, Table S1 , and Fig. S4 ).
Discussion
In this study, we demonstrated for the first time that systemic AAV gene transfer is feasible in a young adult dystrophic large mammal. Bodywide delivery to skeletal and cardiac muscle was confirmed in three affected dogs using two different AAV vectors. Notably, efficient whole body muscle transduction was not associated with any serious complications. All treated dogs tolerated gene transfer well and maintained the expected body weight growth (Fig. 1B) . This is encouraging considering the fact that up to 2 × 10 15 vg AAV particles were delivered to dogs that have ongoing massive muscle degeneration, necrosis and inflammation. Systemic gene delivery has been a long-standing barrier in the field of gene therapy. This barrier was partially broken a decade ago when a series of studies from several laboratories showed robust whole body gene transfer in rodents with AAV-6, 8 and 9 at the dose of ∼0.5-2 × 10 14 vg particles/kg body weight (6) (7) (8) 23 ). Yet, scaling-up systemic AAV delivery to large mammals remains a formidable challenge (18) . There are several obstacles. First, the thick basement membrane in large mammals may significantly limit vector spread from the microvasculature. It is thus expected that systemic transduction efficiency in large mammals will be reduced compared with that of mice. In support of this notion, the vector dose (1 × 10 14 vg/kg) that leads to bodywide gene transfer in adult mice yields much lower transduction in newborn dogs (8, 13) . The second obstacle is the large-scale AAV production. Besides the high cost and intense labor, negligible contaminants will become a significant safety concern when trillions of viral particles are administrated. A third obstacle is our body's response to the infused virus. Unexpected inflammatory and/or immune response may lead to fatal complications as demonstrated in the tragic death of Jesse Gelsinger in a 1998 clinical trial and in the premature termination of the study reported by Kornegay et al. (4, 5) . Lastly, although AAV is much less immunogenic than vectors based on some other viruses (such as adenovirus), affected dogs often mount a furious immune response to AAV. This may further worsen untoward immune rejection to the AAV vector and/or AAV transduced myofibers (1, 24) . Taken together, development of systemic AAV gene transfer in adult dystrophic dogs represents an unprecedented challenge. In light of the clinical need for bodywide gene therapy for DMD, we explored the safety and feasibility of intravenous AAV injection in the canine model, the best large animal model for DMD (25) . To gain a comprehensive view on both muscle and non-muscle gene transfer, we first tested an AP reporter vector at a dose close to the effective dose we have used in normal neonatal puppies (∼2 × 10 14 vg/kg) ( Table 1 ) (13, 16) . Consistent with the results of our newborn dog studies (13, 16) , single intravenous injection yielded bodywide skeletal muscle transduction in the juvenile DMD dog (Fig. 2) . In newborn puppies, saturated transduction was observed in every skeletal muscle (13, 16) . However, in the young adult dystrophic dog, only the EOM showed near complete transduction (80%). We have previously found that myocardium expression from AAV-9 and Y731F AAV-9 was selectively blocked at some undefined post-entry steps in newborn dogs (13, 16, 17) . In these published studies, we detected the AAV genome in the heart but AP positive cells were rarely observed. In striking contrast, efficient AP expression was seen in the heart of the young adult dystrophic dog suggesting that certain age and/or disease-related changes in the cardiomyocytes may have facilitated cardiac AAV-9 transduction in the juvenile DMD dog. The cellular mechanism of systemic AAV muscle transduction is poorly understood. However, it is generally believed that viral particles have to cross the blood vessels to reach muscle. Consistent with this notion, we observed efficient microvasculature transduction in muscle (Fig. 3E) . It has been shown that AAV-9 can cross the blood-brain barrier and transduce the central nerve system (26, 27) . We indeed observed a high-level transduction in the spinal cord. Intriguingly, there was nominal AP expression in the cerebrum and cerebellum (Fig. 3D) . Nevertheless, the peripheral nerves (including large nerves such as the sciatic nerve and small nerve branches such as these inside muscle) were effectively transduced ( Fig. 3C and D) .
Following systemic gene transfer, a significant amount of viral particles is often sponged in the liver. Zincarelli et al. compared nine AAV serotypes (AAV-1 to AAV-9) in mice and found that AAV-9 yielded the highest expression in the liver. In sharp contrast, we did not see strong liver expression in either normal newborn puppies or adult dystrophic dogs (Fig. 3) (13,15-17) . There was also minimal expression in the testis, kidney, pancreas and lung (Fig. 3) . Interestingly, we detected a high abundance of the AAV genome in internal organs (Fig. 3) . Our results suggest that there may exist important species differences in AAV transduction. The inconsistency between the AAV genome copy number and the level of transgene expression in the liver is somewhat unexpected. The exact mechanisms behind this peculiar finding remain to be dissected. We speculate that it may relate to promoter silencing or inefficient conversion of the single-stranded AAV genome to the double stranded transcription competent form in the dog liver.
To confirm and expand our findings with the reporter AAV vector, we next performed a dose escalation study with a μDys vector in two affected dogs. One dog received a total of 1.77 × 10 Table 1 ). These doses are lower than the highest does we have delivered to newborn normal dogs (9.65 × 10 14 vg/kg) (17) . However, as to our knowledge, they are the highest AAV doses ever been delivered to a diseased large mammal. Considering the potential immunogenicity of dystrophin (24, 28) , we extended immune suppression to the end of the study (Fig. 1A) . Despite prolonged immune suppression and the increased AAV dose, we did not see adverse reactions in either dog. Blood examination did not show any evidence of liver or kidney damage (Fig. 1C , and Supplementary Material, Table S1 ). Together with the results of the AP vector injected dog, we conclude that there is minimal risk for systemic AAV gene transfer in adolescent dystrophic dogs. To verify bodywide muscle transduction in μDys vector injected dogs, we performed immunostaining and western blot (Fig. 4) . These studies revealed the correct sarcolemmal localization and expected molecular size of μDys (Fig. 4) . Consistent with what we saw in the AP vector injected dog, widespread μDys expression was detected in every muscle including the heart (Fig. 4) . Although there were muscle-to-muscle differences, on average transduction efficiency reached ∼25%.
The dog Brooke was injected with a dose 25% greater than what was administrated to the dog Stephan (Table 1) . We initially expected Brooke to have higher expression. However, this turned out not to be the case. On biopsy, Stephan seemed to have a slightly better expression and it also had more AAV genome copy (Fig. 1) . The necropsy samples from Brooke's skeletal muscle, in general, had expression higher than those from Stephan's (Fig. 4) . But Stephan appeared to have a better expression in the heart (Fig. 4) . Interestingly, compared with Stephan, Brooke had a lower AAV genome copy number in most skeletal muscle and heart samples. We suspect that individual differences (such as gender, body weight at injection, vector dose, necropsy age and other yet unknown factors) may have contributed to these observations.
The EOM consistently showed the highest expression in all three treated dogs. The exact mechanism(s) underlying preferential EOM transduction is yet to be elucidated. But it should be pointed out that this muscle indeed carries some unique biological features. For example, it is the only muscle in the dog body with the type IIB myofiber (29) (Duan D, unpublished observation) .
In the neonatal study conducted by Kornegay and colleagues, dogs were not administrated with immune suppressive drugs. We have previously shown that transient immune suppression is necessary to achieve efficient local AAV transduction in DMD dog muscles (21, 22) . Based on the same premise, we applied transient immune suppression in this study (Fig. 1A) . Interestingly, two recent reports showed effective AAV-1 and AAV-8 delivery of an oligonucleotide via regional intravascular administration in dystrophic dogs without using immunosuppression (30, 31) . Future side-by-side comparison is needed to clarify the role of the AAV serotype (AAV-1 and AAV-8 versus AAV-9) and the transgene product (oligonucleotides versus proteins) in vascular delivery in DMD dogs.
Since our long-term goal is systemic DMD gene therapy, we examined muscle pathology in all three injected dogs. As expected, delivery of a reporter gene AAV vector yielded no protection (Fig. 5A) . The muscle still displayed characteristic dystrophic features. Two dogs received μDys therapy (Fig. 4) . Different levels of mosaic expression were observed in various muscles in these dogs. The extensor carp ulnaris muscle had 5% μDys-positive myofibers. Neither morphology nor function was improved in this muscle. However, we noticed an encouraging trend of pathology amelioration in muscles that had μDys expression in more than 25% myofibers (Fig. 5) . This result is consistent with the reports from other groups (30) (31) (32) (33) (34) . Collectively, these data suggest that threshold non-uniform dystrophin expression can protect muscle. Despite histology improvement in many muscles, we did not see consistent reduction in serum creatine kinase. This could either because not all muscles were protected at the current doses or because the sample size is too small in our study. Future large-scale high-dose studies are warranted to thoroughly evaluate whole body μDys therapy in dystrophic dogs. Alternatively, other AAV serotypes should be explored to identify capsids that are more potent. It should also be pointed out that we have only followed AAV injected dogs for 3-3.5 months. Future longterm studies are warranted to assess the extent and persistence of systemic delivery in affected dogs.
In summary, we have demonstrated for the first time that intravenous Y731F AAV-9 administration can lead to efficient bodywide muscle transduction in young adult dystrophic dogs. The procedure is safe at the dose as high as 6.24 × 10 14 vg particles/kg body weight (2 × 10 15 vg particles per dog). While our study has opened the door to the possibility of bodywide AAV μDys gene therapy in young DMD patients in the future, additional works are needed to assess long-term safety and efficacy. Nevertheless, preliminary reports from systemic AAV-9 delivery in spinal muscular atrophy patients have yielded encouraging safety data (trial # NCT02122952) supporting continuous development of systemic AAV gene therapy for human diseases.
Materials and Methods

Animals
All animal experiments were approved by the Animal Care and Use Committees of the University of Missouri and were in accordance with the National Institutes of Health guidelines. Three dystrophin-deficient dogs were used in this study (Table 1 ). All three dogs were seronegative for AAV-9 before injection. Each dog carried a different null mutation in the dystrophin gene (18) .
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Specifically, the dog Bouchelle had a repetitive element insertion in the intron 19 of the dystrophin gene. This insertion introduced a nonsense mutation, which abolished dystrophin expression (18) . In the dog Stephan, a point mutation in intron 6 disrupted dystrophin RNA splicing and the resulting transcript contained frame-shift mutation and a premature stop codon (35) . In the dog Brooke, the long interspersed repetitive element-1 was inserted in the intron 13 of the dystrophin gene. Insertion created a new exon containing an in-frame stop codon (36) . All experimental dogs were generated by artificial insemination and were on a mixed genetic background of golden retriever, Labrador retriever, beagle and Welsh corgi. The genotyping was determined by polymerase chain reaction (PCR) as we previously described (36, 37) .
Recombinant Y731F tyrosine mutant AAV-9 production and gene delivery
The Y731F AAV-9 capsid-packaging construct has been published before (21, 38) . The AP reporter vector was published before (13, 16) . In this vector, the ubiquitous RSV promoter controls AP expression. This plasmid has been described previously. The canine micro-dystrophin AAV stock (CMV.μDys) was produced using our published construct pSJ46 (21) . In the CMV.μDys vector, the codon-optimized canine ΔR2-15/ΔR18-19/ΔR20-23/ΔC microgene was expressed under the control of the CMV promoter (21) . Recombinant endotoxin-free AAV vectors were generated using the triple plasmids transfection method we described before (39) . Viral titer was determined using the Fast SYBR Green Master Mix kit (Bio-Rad, Hercules, CA) by real-time quantitative PCR (qPCR) in an ABI 7900 HT qPCR machine (Applied Biosystems). For RSV.AP virus, the forward primer for viral titer quantification was 5′-GGTTGTACGCGGTTAGGAGT and the reverse primer was 5′-GGCATGTTGCTAACTCATCG. This primer set amplified a fragment in the RSV promoter. For CMV.μDys virus, the titer was determined by qPCR using primers that amplified exons 69 and 70 in the dystrophin CR domain. The forward primer is 5′-TTTTCTGGTCGAGTTGCAAAAG. The reverse primer is 5′-CCATGTTGTCCCCCTCTAAGAC.
Immune suppression
Immune suppression was applied to experimental dogs using cyclosporine (Neoral, 100 mg/ml; Novartis, East Hanover, NJ; NDC 0078-0274-22) and mycophenolate mofetil (CellCept, 200 mg/ml; Genentech, South San Francisco, CA; NDC 0004-0261-29) (21, 22) . Cyclosporine was administered orally at the dose of 10-20/mg/kg/day to achieve a whole blood trough level of 100-200 ng/ml. The cyclosporine level was measured at the Clinical Pathology Laboratory in the University of Missouri Hospital (Columbia, MO). The blood trough level was achieved at ∼6 days after starting cyclosporine. Mycophenolate mofetil was administered orally twice a day at the dose of 20 mg/kg (40 mg/kg/ day). Immune suppression was started at 1 week prior to AAV injection. Immune suppression was continued for 4 weeks after AAV injection for Bouchelle and throughout the entire experiment for Stephan and Brooke (Fig. 1 ).
Gene delivery, muscle biopsy and dog necropsy
Systemic Y731F AAV-9 delivery was performed in conscious dogs by a single intravenous injection through the cephalic vein (Table 1) . Biopsy was performed on the BF and CT at 1 month after AAV injection (14) . Necropsy was performed at 3.5 months post-injection for Bouchelle and Stephan and 4 months post-injection for Brooke. During necropsy, major skeletal muscles from the head (EOM, temporalis, tongue), neck (sternocephalicus), shoulder (deltoideus, supraspinatus), thorax (intercostal muscle, pectoralis), back (latissimus, teres, trapezius), abdomen (abdominal rectus), forelimb (biceps brachii, brachialis, extensor carpi radialis, ECU, extensor digitorum communis, flexor carpi radialis, flexor carpi ulnaris, flexor digitorum, pronator, TB) and hind limb (BF, cranial sartorius, CT, extensor digitorum lateralis, extensor digitorum longus, gastrocnemius, gracilis, quadriceps, rectus femoris, semimembranosus, semitendinosus, vastus lateralis and vastus medialis) as well as the diaphragm (sternal, costal and lumbar part), heart (right and left atria, right and left ventricles, papillary muscles and interventricular septum) and internal organs (liver, pancreas, spleen, lung, kidney, gonad, spinal cord, brachial plexus, sciatic nerve, cerebrum, cerebellum and hippocampus) were harvested. Two pieces of samples were collected from each tissue. One piece was frozen in liquid nitrogen-cooled isopentane in optimal cutting temperature media for cryosection and histological examinations. The other piece was snap frozen in liquid nitrogen for genomic DNA and protein extraction.
Blood chemistry
Blood was drawn from experimental subjects before the start of immune suppression (baseline data) and periodically throughout the experiment (Supplementary Material, Table S1 ). The laboratory biochemical test was performed at the Veterinary Medical Diagnostic Laboratory in the University of Missouri Veterinary Medical Teaching Hospital (Columbia, MO).
Histological examination of AP reporter gene expression AP histochemical staining was carried out on 8-µm-thick cryosections as we described before (13, 14, 22) . Briefly, tissue sections were fixed in 0.5% glutaraldehyde for 10 min. After washing with 1 mM MgCl 2 , slides were incubated at 65°C for 45 min to inactivate endogenous AP activity. Slides were subsequently washed in a pre-staining buffer containing 100 mM Tris-HCl, pH 9.5, 50 mM MgCl 2 , 100 mM NaCl. Finally, slides were stained in the freshly prepared AP staining solution (165 mg/mL 5-bromo-4-chloro-3-indolylphosphate-p-toluidine, 330 mg/ml nitroblue tetrazolium chloride, 50 mM levamisole) for 5-20 min. Cryosections from an uninfected dog (Frank) were used as negative controls for AP staining (13) .
Examination of AP activity assay in tissue lysate
Total protein lysate was extracted as we described before (14) . Protein concentration was determined using the DC protein assay kit (Bio-Rad). AP activity was measured by a colorimetric method using the Stem TAGTM alkaline phosphatase activity assay kit (Cell Biolabs, San Diego, CA). Prior to the assay, endogenous AP activity was inactivated by incubating the lysate at 65°C for 1 h.
Examination of μDys expression by immunofluorescence staining
Codon-optimized flag-tagged canine ΔR2-15/ΔR18-19/ΔR20-23/ΔC μDys was revealed with an anti-FLAG M2 antibody (1:400; Sigma). μDys expression was also confirmed with a dystrophin C-terminal Dys-2 epitope specific antibody (1:20; Novocastra, Newcastle, UK).
Western blot
Whole muscle lysate was loaded on an 8% sodium dodecyl sulfate-polyacrylamide gel, and protein was transferred to a polyvinylidene difluoride membrane. Dystrophin was detected with an antibody against the Dys2 epitope (1:100; Novocastra). The fulllength dystrophin protein migrated at 427 kD. The canine ΔR2-15/ΔR18-19/ΔR20-23/ΔC μDys protein migrated at 140 kD.
Vector genome copy number determination
Genomic DNA was extracted from freshly frozen tissue samples. The AAV genome copy was determined using the Fast SYBR Green Master Mix kit (Applied Biosystems) by qPCR in an ABI 7900 HT qPCR machine. A set of primers located within the AP gene was employed to quantify the vg copy number in Bouchelle. The forward primer is 5′-GACTGAGCCCATGACACCAA. The reverse primer is 5′-CATCTGTCTCGACCCCACTG. For Stephan and Brooke, we used a set of primers that amplified a 119 bp fragment in the CMV early enhancer. The forward primer is 5′-TTACGG TAAACTGCCCACTTG. The reverse primer is 5′-CATAAGGTCA TGTACTGGGCATAA.
In situ muscle force assay
Prior to necropsy, the contractility of the ECU muscle was measured according to our published protocol (21, 40) .
Supplementary Material
Supplementary Material is available at HMG online.
